US OptionsDetailed Quotes
ARAY250117P2000
- 0.00
- 0.000.00%
15min DelayClose Dec 27 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover31.34%IV-9.29%PremiumJan 17, 2025Expiry Date0.17Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8807Delta1.6954Gamma10.46Leverage Ratio-0.0005Theta-0.0006Rho-9.21Eff Leverage0.0008Vega
Accuray Stock Discussion
Benzinga· just
Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications
Benzinga· 3 mins ago
The research builds on previously reported data and shows that at five years, stereotactic body radiation therapy (SBRT) provides comparable rates of cancer control, tolerability and sexual functioning to conventional radiotherapy (CRT), while reducing the overall treatment timeframe from up to 39 days ...
8 MINUTES AGO, 5:30 PM EDT
VIA PR NEWSWIRE
The Technology Will Play an Important Role in the Hospital's Plan to Expand Patient Access to High Precision Radiation Therapy Treatments
MADISON, Wis., Sept. 10, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Gifu Prefectural Gene...
Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution
Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix™
Accuray Incorporated (NASDAQ: ARAY) has received CE Mark for Accuray Helix™, a new CT-guided helical radiotherapy system designed for emerging markets with access to advanced cancer care. The system aims to provide high-performance, high-throughput radiotherapy in non-urban communities, offering short treatment times and cost-effectiveness.
Accuray Helix is part of the company's strategic...
📊⚡️📊
Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results
▪️Positive
Q4 revenue increased 13.5% year-over-year to $134.3 million
Q4 net income of $3.4 million, compared to a loss in the prior year
Q4 gross orders increased 7.9% to $95.5 million
Record quarterly system shipments, up 24% year-over-year
Q4 Adjusted EBITDA nearly doubled to $10.1 million
Full year gross orders increased 10% to $342.1 million
Gained approval for Accuray Precision Treatment Planni...
Halifax Health in Florida is First in the U.S. to Treat Patients with Cancer Using the Accuray Radixact® Radiation Delivery System and VitalHold™ Technology
Halifax Health in Florida has become the first in the U.S. to treat cancer patients using the Accuray Radixact® System with VitalHold™ technology. This advanced system, housed at the Cancer Center for Hope – Port Orange, combines ClearRT® helical CT imaging and Synchrony® real-time adaptive delivery technologies to enh...
No comment yet